Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accesswire.com/847235/pieris-pharmaceuticals-announces-strategy-to-maximize-partnered-milestone-and-royalty-potential
https://www.fiercebiotech.com/biotech/astrazeneca-bails-pieris-asthma-asset-thrusting-biotech-restructuring-70-layoffs
https://www.clinicaltrialsarena.com/news/pieris-review-asthma-drug/
https://www.fiercebiotech.com/biotech/too-many-cooks-kitchen-pieris-culls-phase-2-cancer-drug-focus-astrazeneca-asthma-collab
https://www.clinicaltrialsarena.com/news/pieris-dosing-gastric-cancer-trial/
https://trialsitenews.com/pieris-pharmaceuticals-announces-first-patient-dosed-phase-2-gastric-cancer-trial-evaluating-4-1bb-her2-bispecific-cinrebafusp-alfa/
https://www.biospace.com/article/releases/pieris-pharmaceuticals-announces-appointments-of-chief-financial-officer-and-chief-business-officer/
https://www.pieris.com/investors/news-events/press-releases/detail/668/pieris-pharmaceuticals-announces-prs-220-presentation-at
https://www.pieris.com/news-media/press-releases/detail/662/pieris-pharmaceuticals-announces-respiratory-and
https://www.businesswire.com/news/home/20210426005047/en/Pieris-Pharmaceuticals-and-Boston-Pharmaceuticals-Enter-into-an-Exclusive-Worldwide-Product-License-for-PRS-342-a-4-1BBGPC3-Immuno-Oncology-Bispecific